Journal of the Neurological Sciences
Volume 247, Issue 2 , Pages 173-179, 25 September 2006

Is ferroportin–hepcidin signaling altered in restless legs syndrome?

  • Stacey L. Clardy

      Affiliations

    • Department of Neurosurgery, M.S. Hershey Medical Center, 500 University Drive, H110, Hershey, PA 17033, USA
    • Tel.: +1 717 531 5203; fax: +1 717 531 0091.
  • ,
  • Xinsheng Wang

      Affiliations

    • Department of Neurosurgery, M.S. Hershey Medical Center, 500 University Drive, H110, Hershey, PA 17033, USA
    • Tel.: +1 717 531 5203; fax: +1 717 531 0091.
  • ,
  • Philip J. Boyer

      Affiliations

    • Department of Pathology, Division of Neuropathology, University of Texas Southwestern, Dallas, TX 75390, USA
  • ,
  • Christopher J. Earley

      Affiliations

    • Department of Neurology, Johns Hopkins School of Medicine, Johns Hopkins Bayview Medical Center, 5501 Hopkins Bayview Circle, Rm 1B-82 Baltimore, MD 21224, USA
    • Tel.: +1 410 550 1044; fax: +1 410 550 3364.
  • ,
  • Richard P. Allen

      Affiliations

    • Department of Neurology, Johns Hopkins School of Medicine, Johns Hopkins Bayview Medical Center, 5501 Hopkins Bayview Circle, Rm 1B-82 Baltimore, MD 21224, USA
  • ,
  • James R. Connor

      Affiliations

    • Department of Neurosurgery, M.S. Hershey Medical Center, 500 University Drive, H110, Hershey, PA 17033, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 717 531 4541; fax: +1 717 531 0091.

Received 16 August 2005; received in revised form 28 March 2006; accepted 10 April 2006.

Abstract 

Restless legs syndrome (RLS) is a neurological disorder characterized by a strong urge to move the legs. Sufferers of RLS often experience chronic sleep deprivation, due to the characteristic worsening of symptoms both when at rest and during the night. MRI data, autopsy studies, and a consistent decrease in CSF ferritin all suggest that early-onset RLS is associated with insufficient iron in the brain. In this study, we examined the relationship between the iron regulatory hormone hepcidin and RLS. Hepcidin serves as a hormone that signals iron release from cells by interacting with ferroportin. We measured the expression and concentration of pro-hepcidin in the brain and cerebrospinal fluid of both RLS patients and control individuals. In CSF, we found that pro-hepcidin levels were significantly decreased in early-onset RLS patient samples, but not in late-onset RLS patients, when compared to controls. Conversely, in neuromelanin cells, substantia nigra, and putamen, the concentration of pro-hepcidin in RLS samples is significantly increased compared to controls. Functionally, hepcidin binds to ferroportin to limit iron movement from cells. Therefore, we provide immunocytochemical evidence that ferroportin is expressed by the epithelial cells of the choroid plexus and the ependymal cells lining the ventricles. These data suggest that sites of action for hepcidin include signaling the ventricular system for movement between brain and CSF. At this time, it cannot be determined if the lower levels of pro-hepcidin in the CSF represent a compensatory response to the decreased levels of iron in the brain or a defective signaling mechanism in RLS. Nonetheless, these data support the mounting evidence that there is a biological basis for RLS and the underlying mechanism involves iron management.

Keywords: Basal ganglia disorders, Movement disorders, Iron, Cerebrospinal fluid (CSF), Laser capture microdissection (LCM), Neuromelanin, Putamen

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was supported by NIH/NCRR grant M01-RR-02719 (Johns Hopkins GCRC). NIH grant RO1-NS038704, Dopaminergic Function in Restless Legs Syndrome (CJE, PI) and a Program project grant from the NIH (1 P01 AG021190) awarded to the group in Pathophysiology of RLS (CJE, PI).

PII: S0022-510X(06)00169-9

doi:10.1016/j.jns.2006.04.008

Journal of the Neurological Sciences
Volume 247, Issue 2 , Pages 173-179, 25 September 2006